Trial Profile
Randomised, Double-blind, Placebo-controlled, Parallel Group Study TroVax, Added to First-line Standard of Care, Prolongs Survival of Patients With Locally Advanced or Metastatic Clear Cell Renal Adenocarcinoma.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 21 Oct 2020
Price :
$35
*
At a glance
- Drugs MVA 5T4 (Primary) ; Interferon alpha; Interleukin-2; Sunitinib
- Indications Renal cancer
- Focus Registrational; Therapeutic Use
- Acronyms TRIST
- Sponsors Oxford BioMedica
- 15 Mar 2011 Results following a further analysis of trial data have been reported in an Oxford BioMedica media release.
- 29 Sep 2010 Primary endpoint 'Overall survival duration' has not been met.
- 29 Sep 2010 Results reported in Clinical Cancer Research.